Eli Lilly and Company

FRC's fair value estimate for Eli Lilly and Company, and the rating behind it. LLY.TO last traded at C$40.88, 38.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Eli Lilly and Company. Starting points for Eli Lilly and Company: P/E 38.4, EPS C$29.93, beta 1.19 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Eli Lilly and Company. Eli Lilly and Company paid C$0.24 per share over the last year — a 0.6% yield at the current C$40.88 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Eli Lilly and Company. Trailing twelve-month EPS for Eli Lilly and Company stands at C$29.93. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Eli Lilly and Company. Eli Lilly and Company has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Eli Lilly and Company valued side by side against its closest peers. Eli Lilly and Company is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Eli Lilly and Company, and how their positions are changing. At a C$1.41T market value, institutional positions materially move Eli Lilly and Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Eli Lilly and Company executives and directors. Shares of Eli Lilly and Company have traded between C$30.67 and C$44.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Eli Lilly and Company. Eli Lilly and Company is a C$1.41T Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Eli Lilly and Company. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Eli Lilly and Company. Coverage tracks Eli Lilly and Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.